Solving Drug Delivery’s Toughest Challenges – From Lab to Life.
Likarda partners with leading biotech, pharma, and research organizations as a trusted formulation and drug delivery partner. We provide enabling technologies for small molecules, biologics and cell therapies using our proprietary Core-Shell Spherification® (CSS®) encapsulation platform.
Core-Shell Spherification®
Our patented CSS® encapsulation technology surrounds cells or therapeutics in customizable hydrogel matrices designed to provide protection, localization, and controlled or sustained delivery.
The platform is fully customizable, enabling precise control over release timing, bead size, and therapeutic payload for a wide range of applications.
Likarda is investing in new manufacturing capabilities to meet the growing demand for our hydrogel delivery platforms. In 2027, we will introduce proprietary CSS® equipment, empowering partners with scalable encapsulation solutions for biologics, cells, and small molecules.
Combine (Hydrogel Precursor + API)
Microparticle Formation
Crosslink Hydrogel
Rinse Process
Quality ControlPowering the Future of Medicine
Likarda is a proven partner to biotech and pharmaceutical companies, delivering revenue-generating solutions today through our advanced hydrogel platforms and drug delivery technologies.
Cell Therapies
Learn more about Cell Therapy SolutionsCell-based encapsulation systems designed to protect, deliver, and sustain the function of living cells at the target site.
Cryopreservation & Logistics
Discover Next-Gen Cryopreservation & LogisticsSolutions designed to protect therapeutic cells and biologic materials during storage and transport—potentially reducing dependence on liquid nitrogen and simplifying cold-chain logistics.
Large & Small Molecules
Explore Delivery Solutions for Large & Small MoleculesCustom hydrogel platforms that enable controlled, extended release and delivery of biologics and small molecule drugs.
Built to Solve the Toughest Therapeutic Challenges
Likarda’s CSS® platform is designed to protect therapeutic cells while enabling controlled, reproducible encapsulation and delivery. Tunable hydrogel properties can be customized to support cell viability, localization, and function based on the needs of each therapeutic application.
Contact us to find out how we can help.
Success StoriesPowered by Likarda
Antibodies (NovoSphere™)
Monthly mAb dosing achieved through lyophilized, extended-release formulation.
Osteoarthritis Therapy (ViscoCell™)
Achieving 4x extended release in preclinical models.
Diabetes Treatment (EnduraCell™)
Sustained blood glucose control without daily insulin injections in preclinical models.
Cryopreservation (LiberaCell™)
Liver spheroids maintained >80% viability and function post-thaw.
Liver Disease (EnduraCell™)
30-day functional liver spheroids outperforming alginate models.
CAR-T Cells (VitaCell™)
Cryopreserved cells delivered with 95% viability post-thaw.
Cryopreservation (AegisCell™)
Enabled safe, effective T-cell cryopreservation and shipment for up to two weeks on dry ice.
Extending the Life of Fresh Cells (LiberaCell™)
LiberaCell™ creates a supportive environment that maintains cell viability and metabolic activity without the need for media exchanges or ultra-cold conditions.
Preserving Islet Viability with Cryopreservation (LiberaCell™)
High viability is maintained for fragile islets used in diabetes research and future transplant applications.
